You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergySBC: ABWIZ BIO INC Topic: NIAID
DESCRIPTION provided by applicant The prevalence of food allergy has been dramatically increasing for the last few decades Food Allergy and Anaphylaxis Network www foodallergy org estimates that up to million Americans have food allergies Six to eight percent of children under the age of three have food allergies and nearly four percent of adults have them Signs and symptoms of food all ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeoVative, Inc. Topic: 400
DESCRIPTION provided by applicant andquot Code blue andquot the term used in hospitals to call for an immediate cardiopulmonary resuscitation CPR signals dire emergencies where medical errors can occur and lives can be lost Reviewing CPR performance of the code blue team is a cornerstone for improving outcomes Thorough and accurate recording of code blue events enable detailed reviews to ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: BIOVINC, LLC Topic: NIDCR
DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Lumina Diagnostics, Inc. Topic: NICHD
DESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: BDI, Inc. Topic: NIAMS
PROJECT SUMMARY ABSTRACT As people age they steadily lose bone mass and their bones become fragile and increasingly prone to hip and other fractures and this can prove fatal The American College of Radiology therefore recommends that assessment of bone mineral density BMD be performed in post menopausal women and all people over the age of every two years If indicated preventive measure ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Sarcoidosis Diagnostic Testing LLC Topic: NHLBI
DESCRIPTION provided by applicant SARCOIDOSIS DIAGNOSTIC TESTING LLC is a medical diagnostics company developing a diagnostic blood test for sarcoidosis Sarcoidosis is a multisystem granulomatous disorder that affects per people per year in the U S and disproportionately affects African Americans and women Sarcoidosis can lead to advanced pulmonary fibrosis pulmonary hyperte ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Vivoscript, Inc. Topic: 200
DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: EyeMedix, Inc. Topic: N
DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: MOLECULAR EXPRESS, INC Topic: NCATS
DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health